Home / Treatments / Genotropin
Genotropin denials: what the review data shows
Independent reviewers have decided 73 published cases where an insurer denied Genotropin — and they overturned the insurer 35.6% of the time. A denial for Genotropin is a starting position, not a final answer.
Published decisions
73
2001–2026
Overturned
35.6%
26 denials reversed
By condition
Published outcomes when Genotropin was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Idiopathic Short Stature | 15 | 40% |
| Short Stature | 13 | 46.2% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Genotropinwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.